Current Research Progress on ABHD5 in Cancers

Area of Science:

• Oncology
• Lipid Metabolism
• Molecular Biology

Background:

• Lipid metabolism is crucial for cancer development and treatment resistance.
• Chanarin-Dorfman syndrome (CDS) highlights the role of alpha/beta-hydrolase domain-containing protein 5 (ABHD5) in lipid droplet mobilization.
• ABHD5's role in cancer is context-dependent, acting as a tumor suppressor in some and a promoter in others.

Purpose of the Study:

• To review the diverse and contradictory roles of ABHD5 in various cancers.
• To map the context-dependent functions and molecular mechanisms of ABHD5 in cancer.
• To explore ABHD5's potential as a diagnostic marker and therapeutic target.

Main Methods:

• Review of experimental and clinical evidence.
• Analysis of ABHD5's interaction with signaling pathways (AMPK/mTOR, AKT, NF-κB).
• Examination of ABHD5's influence on cancer hallmarks (proliferation, invasion, apoptosis, immune evasion, drug response).

Main Results:

• ABHD5 restrains tumor growth in lung, liver, and renal cell carcinoma.
• ABHD5 promotes malignant progression in endometrial cancer.
• ABHD5 has context-dependent roles in colorectal and prostate cancers.
• ABHD5 influences cancer cell fate and behavior through key signaling pathways.

Conclusions:

• ABHD5 exhibits context-specific functions in cancer, necessitating nuanced therapeutic strategies.
• ABHD5's complex roles warrant further investigation as a potential diagnostic and therapeutic target.
• Understanding ABHD5's molecular circuits is key to developing targeted anticancer interventions.